Syneron Bio raised $150 million in a Series B round to develop a peptide drug class designed to borrow some of the properties of biologics. The company said the financing will support development of its peptide pipeline and comes after a $100 million round last year. The funding adds to a growing investor push into peptide modalities that aim to combine targeting specificity with improved dosing and manufacturing profiles compared with antibodies. With the round following earlier collaboration activity, Syneron’s next milestones will likely focus on advancing candidates toward clinical proof points and differentiating within a crowded peptide landscape.